Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Neuroprotective effects of new PARS inhibitor

Jan. 26, 1998

Agents for schizophrenia without EPS disclosed by Warner-Lambert

Jan. 26, 1998

Antegren meets development criteria in phase II trial

Jan. 23, 1998

CRF antagonists patented by Pfizer

Jan. 23, 1998

Enantiomers of trans-benz[e]indoles selective for D3 receptors

Jan. 23, 1998

Orally active enkephalinase-inhibitory prodrug reported by Dainippon

Jan. 23, 1998

Titan reports results from preclinical Parkinson's trial

Jan. 22, 1998

HMR and Allelix end collaboration for treatment of schizophrenia

Jan. 22, 1998

HMR and Abbott sign marketing agreement for Anzemet

Jan. 22, 1998

Botox compared to saline for chronic anal fissure

Jan. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...